Scroll
To Top

Analyzing Trends in Orphan Drugs and Expenditures

NORD_quintiles-ims-reports_2Quintiles IMS issued a study which finds that orphan drugs accounted for only 7.9% of total drug sales in the U.S. in 2016. This study, released on October 17, 2017, was commissioned by NORD and analyzed the role of the Orphan Drug Act and orphan drug usage and costs, to address a number of public policy and health care financing issues in the rare disease community.

 

 

 

Download the report and NORD’s white paper by filling out the form below.

  • This field is for validation purposes and should be left unchanged.